Literature DB >> 10470287

Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.

Y Morita1, Y Hayashi, T Kanamaru, T Itoh, S Suzuki, M Yamamoto, Y Kuroda, H Itoh.   

Abstract

Plasminogen activator inhibitor (PAI)-1, a serine protease inhibitor, inactivates urokinase-type plasminogen activator (uPA) and regulates degradation of the extracellular matrix; whether it functions for or against tumor progression, however, has been the subject of controversy. To assess the role of PAI-1 in invasion and proliferation of hepatocellular carcinoma (HCC) cells, HLE cells were transfected with a vector capable of expressing an antisense PAI-1 transcript. Analysis of seven stably transfected clones (PAI-1-) showed reductions of 81% in PAI-1 mRNA by northern blot analysis and 63% in the cellular PAI-1 antigen level by enzyme-linked immunosorbent assay (ELISA). There was no change in the levels of secreted PAI-1 or PAI-2. The activity of cellular uPA increased by 54%, without change in the protein level or the secreted uPA activity evaluated by ELISA. Morphologically, PAI-1 antisense induced a spindle shape with narrower cytoplasmic processes in HLE cells. The forced inhibition of PAI-1 increased the invasion and the growth of PAI-1- cells by 75% and 82%, respectively. These results suggest that PAI-1 plays a role in inhibiting invasion and proliferation, and the balance between uPA and PAI-1 expression is important to assess the invasiveness of HCC cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10470287      PMCID: PMC5926134          DOI: 10.1111/j.1349-7006.1999.tb00810.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  26 in total

Review 1.  Plasminogen activator inhibitors: hormonally regulated serpins.

Authors:  P A Andreasen; B Georg; L R Lund; A Riccio; S N Stacey
Journal:  Mol Cell Endocrinol       Date:  1990-01-02       Impact factor: 4.102

2.  Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.

Authors:  D A Waltz; L R Natkin; R M Fujita; Y Wei; H A Chapman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.

Authors:  J Jankun; R W Keck; E Skrzypczak-Jankun; R Swiercz
Journal:  Cancer Res       Date:  1997-02-15       Impact factor: 12.701

Review 4.  Plasminogen activator inhibitors--a review.

Authors:  E K Kruithof
Journal:  Enzyme       Date:  1988

5.  Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumour virus chimaeric plasmids.

Authors:  F Lee; R Mulligan; P Berg; G Ringold
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

6.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

Authors:  G A Soff; J Sanderowitz; S Gately; E Verrusio; I Weiss; S Brem; H C Kwaan
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

7.  Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma.

Authors:  Y Morita; Y Hayashi; Y Wang; T Kanamaru; S Suzuki; K Kawasaki; K Ohta; M Yamamoto; Y Saitoh; H Itoh; W F Doe
Journal:  Hepatology       Date:  1997-04       Impact factor: 17.425

8.  Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor.

Authors:  W M Mars; T H Kim; D B Stolz; M L Liu; G K Michalopoulos
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

9.  Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways.

Authors:  A M Montgomery; Y A De Clerck; K E Langley; R A Reisfeld; B M Mueller
Journal:  Cancer Res       Date:  1993-02-01       Impact factor: 12.701

10.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Authors:  G Deng; S A Curriden; S Wang; S Rosenberg; D J Loskutoff
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  2 in total

1.  Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.

Authors:  Nobuaki Nishioka; Tasuku Matsuoka; Masakazu Yashiro; Kosei Hirakawa; Kenneth Olden; John D Roberts
Journal:  Cancer Sci       Date:  2012-01-09       Impact factor: 6.716

Review 2.  Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.